Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats

Journal of Neurochemistry

Volumn 95, Issue 4, 2005, Pages 950-961

  Inden, Masatoshi ^a   Kitamura, Yoshihisa ^a   Kondo, Jun Ichi ^a   Hayashi, Kousuke ^a   Yanagida, Takashi ^a   Takata, Kazuyuki ^a   Tsuchiya, Daiju ^a   Yanagisawa, Daijiro ^a   Nishimura, Kaneyasu ^a   Taniguchi, Takashi ^a   Shimohama, Shun ^b   Sugimoto, Hachiro ^b   Akaike, Akinori ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

6 hydroxydopamine; Neuroprotection; Parkinson's disease; Reactive oxygen species; Serofendic acid; Substantia nigra

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ALPHA SYNUCLEIN; APOMORPHINE; BIOLOGICAL MARKER; METHAMPHETAMINE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; SEROFENDIC ACID; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ADMINISTRATION ROUTE; FETAL CALF SERUM; GLIA; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTRANIGRAL DRUG ADMINISTRATION; MALE; MICROINJECTION; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTATION; SUBSTANTIA NIGRA;

ADRENERGIC AGENTS; ALDEHYDES; ALPHA-SYNUCLEIN; ANIMALS; ANTIGENS, CD11B; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CELL COUNT; CELL LINE; DISEASE MODELS, ANIMAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; ROTAROD PERFORMANCE TEST; ROTATION; SUBSTANTIA NIGRA; SYNAPTOPHYSIN; TIME FACTORS; TYROSINE; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PARKINSONIA;

EID: 28244495943     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03413.x     Document Type: Article

References (39)

1. Akaike A., Katsuki H. and Kume T. (2003) Pharmacological and physiological properties of serofendic acid, a novel neuroprotective substance isolated from fetal calf serum. Life Sci. 14, 263-269.
2. Alam Z. I., Jenner A., Daniel S. E., Lees A. J., Cairns N., Marsden C. D., Jenner P. and Halliwell B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-1203.
3. Blum D., Torch S., Lambeng N., Nissou M.-F., Benabid A.-L., Sadoul R. and Verna J.-M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
4. Conway K., Harper J. and Lansbury P. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318-1320.
5. Deumens R., Blokland A. and Prickaerts J. (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175, 303-317.
6. Dunnett S. B. and Björklund A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32-A39.
7. Gee P. and Davison A. J. (1989) Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. Free Radic. Biol. Med. 6, 271-284.
8. Glinka Y. Y. and Youdim M. B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292, 329-332.
9. Good P. R., Hus A., Werner P., Perl D. P. and Olanow C. W. (1998) Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342.
10. Hashimoto M. and Masliah E. (1999) Alpha-synuclein in Lewy body disease and Alzheimer'is disease. Brain Pathol. 9, 707-720.
11. Hashimoto M., Hernandez-Ruiz S., Hsu L., Sisk A., Xia Y., Takeda A., Sundsmo M. and Masliah E. (1998) Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301-306.
12. Heikkila R. E. and Nicklas W. J. (1971) Inhibition of biogenic amine uptake by hydrogen peroxide: mechanism for toxic effects of 6-hydroxydopamine. Science 172, 1257-1258.
13. Inden M., Kondo J., Kitamura Y., Takata K., Tsuchiya D., Nishimura K., Taniguchi T., Sawada H. and Shimohama S. (2003) Differences in rotational asymmetry in rats caused by single intranigral injections of 6-hydroxydopamine, 1-methyl-4-phenylpyridinium ion and rotenone. Biogenic Amines 17, 281-291.
14. Inden M., Kim D., Gu Y. et al. (2004) Pharmacological characteristic of rotational behavior in hemiparkinsonian rats transplanted with mouse embryonic stem cell-derived neurons. J. Pharmacol. Sci. 96, 53-64.
15. Inden M., Kondo J., Kitamura Y., Takata K., Nishimura K., Taniguchi T., Sawada H. and Shimohama S. (2005) Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J. Pharmacol. Sci. 97, 203-211.
16. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A. R., Kittel A. and Saitoh T. (1995) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 15, 467-475.
17. Kettenmarm H. and Ransom B. R. (1995) Neuroglia. Oxford University Press, Oxford.
18. Kitamura Y. and Nomura Y. (2003) Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. Pharmacol Ther. 97, 35-53.
19. Kitamura Y., Kosaka T., Kakimura J., Matsuoka Y., Kohno Y., Nomura Y. and Taniguchi T. (1998) Protective effects of antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54, 1046-1054.
20. Krüger R., Kuhn W. M.,ller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J., Schols L. and Reiss O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
21. Kume T., Kohchiyama H., Nishikawa H., Maeda T., Kaneko S., Akaike A., Noda N. and Fujita T. (1997) Ether extract of fetal calf serum protects cultured rat cortical neurons against glutamate cytotoxicity. Jpn J. Pharmacol. 73, 371-374.
22. Kume T., Asai N., Nishikawa H. et al. (2002) Isolation of a diterpenoid substance with potent neuroprotective activity from fetal calf serum. Proc. Natl Acad. Sci. USA 99, 3288-3293.
23. Kume T., Katsuki H. and Akaike A. (2004) Endogenous factors regulating neuronal death induced by radical stress. Biol. Pharm. Bull. 27, 964-967.
24. Li L., Shen Y. M., Yang X. S., Wu W. L., Wang B. G., Chen Z. H. and Hao X. J. (2002) Effects of spiramine T on antioxidant enzymatic activities and nitric oxide production in cerebral ischemia-reperfusion gerbils. Brain Res. 944, 205-209.
25. Osakada F., Kawato Y., Kume T., Katsuki H., Sugimoto H. and Akaike A. (2004) Serofendic acid, a sulfur-containing diterpenoid derived from fetal calf serum, attenuates reactive oxygen species-induced oxidative stress in cultured striatal neurons. J. Pharmacol. Exp. Ther. 311, 51-59.
26. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, Tokyo.
27. Pedersen W. A., Fu W., Keller J. N., Markesbery W. R., Appel S., Smith R. G., Kasarskis E. and Mattson M. P. (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 44, 819-824.
28. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
29. Ranjita B., Todd B. S. and Greenamyre J. T. (2002) Animal models of Parkinson's disease. Bioessays 24, 308-318.
30. Seitz G., Stegmann H. B., Jager H. H., Schlide H. M., Wolburg H., Roginsky V. A., Niethammer D. and Bruchelt G. (2000) Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine. J. Neurochem. 75, 511-520.
31. Shasi V. K., Sonya C., Srigiridhar K., Joy J., Cecilia J. H. and Kalyanaman B. (2004) α-Synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells. J. Biol. Chem. 279, 15 240-25 247.
32. Shimohama S., Sawada H., Kitamura Y. and Taniguchi T. (2003) Disease model: Parkinson's disease. Trends Mol. Med. 9, 360-365.
33. Smith R. G., Henry Y. K., Mattson M. P. and Appel S. H. (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol. 44, 696-699.
34. Taguchi R., Nishikawa H., Kume T., Terauchi T., Kaneko S., Katsuki H., Yonaga M., Sugimoto H. and Akaike A. (2003) Serofendic acid prevents acute glutamate neurotoxicity in cultured cortical neurons. Eur. J. Pharmacol. 477, 195-203.
35. Takata K., Kitamura Y., Tsuchiya D., Kawasaki T., Taniguchi T. and Shimohama S. (2004) High mobility group box protein-1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity. J. Neurosci. Res. 78, 880-891.
36. Terauchi T., Asai N., Yonaga M., Kume T., Akaike A. and Sugimoto H. (2002) Synthesis and absolute configuration of serofendic acids. Tetrahedron Lett. 43, 3625-3628.
37. Trojanowski J., Goedert M., Iwatsubo T. and Lee V. (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5, 832-837.
38. Ungerstedt U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
39. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. and Przedborski S. (2000) α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.